Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Etoposide and Cisplatin for Neoadjuvant Neuroendocrine Cervix Carcinoma
NCT05910177Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Neuroendocrine carcinoma of the cervix (NECC), sponsored by Fujian Medical University Cancer Hospital. Started Dec 2023; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Neuroendocrine carcinoma of the cervix (NECC)
Beyond the preview
Go deeper on NCT05910177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910177.